Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02057640 · OUTCOME

Overall Survival

MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma · Source last updated 2019-12-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
up to 3 years from start of treatment

What was measured

Overall survival for all will be the number of months from study entry to death from any cause.

Groups in this outcome

DL1 - 3mg Lxazomib

Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 3mg on day 1, 8, 15, 28

DL2 - 4mg Lxazomib

Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 3mg on day 1, 8, 15, 28

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
DL1 - 3mg Lxazomib4
DL2 - 4mg Lxazomib12

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
DL1 - 3mg Lxazomib12.8Not reported1.730.4Not reported
DL2 - 4mg Lxazomib17.6Not reported11.922.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.7
        upper Limit
        30.4
        value
        12.8
      2. group Id
        OG001
        lower Limit
        11.9
        upper Limit
        22.9
        value
        17.6
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      12
    units
    Participants
description
Overall survival for all will be the number of months from study entry to death from any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 3mg on day 1, 8, 15, 28
    id
    OG000
    title
    DL1 - 3mg Lxazomib
  2. description
    Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 3mg on day 1, 8, 15, 28
    id
    OG001
    title
    DL2 - 4mg Lxazomib
param Type
MEDIAN
reporting Status
POSTED
time Frame
up to 3 years from start of treatment
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice